The purposes of this are:

• To determine the highest doses of Taxol and Navelbine that we can safely give to patients;
• To determine what kind of side effects are caused by the combination of Taxol, Navelbine and G-CSF;
• To determine whether the combination of Taxol, Navelbine and G-CSF is more effective than standard therapy in treating metastatic breast cancer and prolonging life;

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

INCLUSION

To be eligible, volunteers must:

• Have stage IV carcinoma of the breast that has been microscopically confirmed
• Be age > 18
• Be fully active or ambulatory with symptoms but able to do light work
• Have a life expectancy of > 16 weeks
• Be > 2 weeks from prior surgery; > 3 weeks from radiation therapy to the pelvis, spine or long bones; > 3 weeks from prior chemotherapy (> 6 weeks for mitomycin C or nitrosureas) and > 2 weeks from prior hormonal therapy
• Have had one or less prior regimens for metastatic disease
• Have measurable (bidimensionally) or evaluable disease that is in an area that has not been radiated

EXCLUSION

Patients are not eligible if they:

• Have rapidly progressing liver or lung metastases or uncontrolled central nervous system metastases
• Are medically unstable
• Are pregnant, nursing or unwilling to employ adequate contraception
• Have pre-existing clinically significant peripheral neuropathy except for abnormalities due to cancer
• Have psychological, familial, sociological or geographical conditions that do not permit weekly medical follow-up and compliance with the study protocol
• Have hypersensitivity to E. Coli-derived proteins, Filgrastim, or any of its components
• Have had prior therapy with Navelbine